Roth Capital’s Yasmeen Rahimi is left bewildered, having banked on the success of OHRP’s wet-AMD asset, but holds out hope to become more positive on the stock down the line.
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …
An article was published on Seeking Alpha detailing a long position.
OHR Pharmaceutical Inc (NASDAQ:OHRP) is confronting the aftermath of Fovista’s pivotal two Phase 3 failures that both missed the primary endpoint in neovascular …
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) announced that it has priced a registered public offering of an aggregate of 3,875,000 shares of common stock at …
OHR Pharmaceutical Inc (NASDAQ:OHRP) announced this afternoon that it intends to offer and sell, subject to market and other conditions, shares of its common …
OHR Pharmaceutical Inc (NASDAQ:OHRP), an ophthalmology research and development company, today reported results for its second quarter ended March 31, 2016. “We achieved a …
OHR Pharmaceutical Inc (NASDAQ:OHRP), an ophthalmology research and development company, announced that David M. Brown, MD, Clinical Professor of Ophthalmology at Baylor College …
OHR Pharmaceutical Inc (NASDAQ:OHRP), a clinical-stage biotechnology company developing novel therapies for ophthalmic diseases, announced that the first patient has been enrolled in the …
Healthcare analysts are weighing in on molecular diagnostics firm TrovaGene Inc (NASDAQ:TROV), pharmaceutical company Keryx Biopharmaceuticals (NASDAQ:KERX), and mological drug maker OHR Pharmaceutical Inc (NASDAQ:OHRP), as the …